Ophthalmology Group Head News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MINNEAPOLIS (BUSINESS WIRE) Jul 15, 2021
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the election of two industry veterans to the Company’s Board of Directors. Amy Burroughs, President and CEO of Cleave Therapeutics, brings over 20 years of experience in business and commercial development, strategy and leadership in the pharmaceutical industry. Dr. Charles Semba, Chief Medical Officer of Eluminex Biosciences, has over 20 years of drug-development experience in high growth public and private therapeutics companies and serves on the faculty of Vascular/Interventional Radiology at Stanford University. ....

United States , Rick Pauls , Eluminex Biosciences , Charles Semba , Cathflo Activase , Scott Kellen , Amy Burroughs , Tim Mccarthy , Lifesci Advisors , Company Board Of Directors , Vascular Interventional Radiology At Stanford University , Diamedica Therapeutics Inc , Ophthalmology Group Head At Genentech , Harvard University , University Of Minnesota , Medica Therapeutics , Cleave Therapeutics , Chief Medical Officer , Interventional Radiology , Chief Executive Officer , Egon Zehnder , Graybug Vision , Vice President Ophthalmic Medicine , Ophthalmology Group Head , Adjunct Professor , Investor Inquiries ,